Paigebin is the domestic polyethylene glycol interferon. The therapeutic effect is as follows: if the patients with triple positive are applied Paigebin, the possibility of triple positive becoming triple positive is 32%, the rate of Hepatitis B virus DNA turning negative reaches 14%, the rate of transaminase normalizing reaches 41%, and the rate of surface antigen turning negative reaches 3%. If Pegabine is applied for hepatitis B minor triple positive, the normalization rate of DNA reaches 19%. Normalization of aminotransferases reaches 59% and surface antigen conversion reaches 3%. The application of pegabine will continue to be observed for three years after the discontinuation of the drug, and the surface antigen conversion rate is 11% for major triple positive and 8% for minor triple positive.